Entero Therapeutics, Inc.
NASDAQ: ENTO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason David Sawyer
- Employees
- 2
- Headquarters
- Boca Raton, United States
- IPO year
- 2016
- Market cap
- $13.6M
- Website
- https://www.firstwavebio.com
Loading ENTO…
Loading profile data…Frequently asked questions about ENTO
What does Entero Therapeutics, Inc. (ENTO) do?
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic c...
Where does ENTO trade?
Entero Therapeutics, Inc. (ENTO) trades on the NASDAQ Capital Market.
What sector is ENTO in?
Entero Therapeutics, Inc. (ENTO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Entero Therapeutics, Inc.?
Jason David Sawyer is the chief executive officer of Entero Therapeutics, Inc. (ENTO).
Where is Entero Therapeutics, Inc. headquartered?
Entero Therapeutics, Inc. is headquartered in United States.
Does ENTO pay a dividend?
Entero Therapeutics, Inc. (ENTO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENTO go public?
Entero Therapeutics, Inc. (ENTO) completed its initial public offering in 2016.